Founded in 1970, Jiangsu Hengrui Medicine is the largest publicly listed and a leading biopharma based in China with 24,700 employees devoted to empowering healthier lives through research. With over $2.5 billion in revenue, Hengrui Medicine has 6 new molecular entities approved in China as well as 30+ programs in clinical development in China, US, and Australia across oncology, anesthesiology & analgesics, autoimmune, and metabolic & cardiovascular diseases. Driven by internal R&D and global licensing and collaboration, Hengrui Medicine is committed to bring high quality products to patients.